Robert C. Goeltz II, Chief Financial Officer at Arcus Biosciences, Inc. (RCUS), sold 1,106 shares at $39.59 ($44K) on 2021-12-16, disclosed to the SEC on 2021-12-20.
Open-market sale of $44k RCUS by Chief Financial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $39.59 | 354 | $14K | 31.6% |
| 2 | $40.46 | 131 | $5K | 11.9% |
| 3 | $38.79 | 138 | $5K | 12.1% |
| 4 | $39.67 | 88 | $3K | 7.9% |
| 5 | $40.57 | 171 | $7K | 15.6% |
| 6 | $41.42 | 224 |
| $9K |
| 20.9% |
| Total | $40.12 avg | 1,106 | $44K | 100% |
| Filing → |
| RCUS | SELL | 2025-12-18 | $557K | — | Filing → |
| RCUS | SELL | 2025-11-26 | $125K | — | Filing → |
| RCUS | SELL | 2025-10-29 | $100K | — | Filing → |